Business Of Biotech

CEO of Aulos Bioscience, Aron Knickerbocker, discusses the first AI antibody in human trials. They explore the innovative IL-2 antibody, AI in molecular design, and recruiting challenges in the biotech industry.

We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. But, while orchestrating a successful drug/device combination therapy presents unique regulatory challenges and requires a diverse array of in-house skillsets, President and CEO Eamon Hobbs is confident. He's done this before, and Syncromune's lead candidate has just been fast-tracked by the FDA. On this episode of the Business of Biotech, Hobbs shares his perspectives on bringing novel drug/device combination therapies to market, and reflects on a career dedicated to the drug delivery craft and demonstrated by his leadership at Antares Pharma, Delcath Systems, AngioDynamics. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

CEO Clarke Atwell from Claris Bio discusses the potential of topically-administered biologic therapies for ocular diseases like Neurotrophic Keratitis. He shares insights on the development progress, funding, and opportunities in the biotech industry. The podcast explores the shift towards patient-friendly eye treatments, the importance of understanding mechanism of action, and the challenges in clinical trials and manufacturing processes.

Lineage Cell Therapeutics' CEO, Brian Culley, discusses overcoming challenges during pandemic, regulatory progress, collaborations with Roche and Genentech, advancements in AMD and spinal cord treatments, organizational transformation, upcoming programs in eye and hearing, cost-effective cell therapy development, and future potentials beyond oncology.

We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to be in it for the long run. Asked about his company’s rapid rise since taking the helm in 2021, CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts. As we head into Juneteenth celebrations, and as pride month comes to a crescendo, we’re all seeing plenty of companies putting a DEI foot forward. Much of this is hollow noise. It’s diversity-washing, the DEI equivalent to greenwashing, whereby organizations misrepresent their environmental practices to create the perception of a commitment to sustainability. Arcellx, and Rami Elghandour, are not that. On this episode of the Business of Biotech, Rami shares vivid lessons from the rise of Arcellx and gets specific on how his steadfast commitment to diversity has fueled its takeoff.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Jonathan Behr, MIT Ph.D. in biological engineering turned venture capitalist, discusses dementia funding, biotech corporate finance, & entrepreneurship. Highlights include strategic investments in dementia research, diversification in funding modalities, challenges in developing disease-modifying drugs, and the importance of a translational mindset in the biotech industry.

Ken Keller, Senior Executive at Daiichi Sankyo, shares the story of Daiichi Sankyo's leap into oncology with ADCs. He discusses the evolution of the ADC market, challenges faced in the transition, scaling a global oncology team, navigating internal challenges, embracing innovation, addressing employee resistance to change, and revolutionizing cancer treatment with ADCs.

Dr. Brian Fiske of Mythic Therapeutics shares his journey transitioning from academia to biotech industry. They discuss developing ADCs for lung cancer, challenges in funding, and strategic planning. The podcast explores Mythic's unique approach in the ADC space and navigating the competitive biotech industry.

Dr. Jason Bock, CEO of CTMC, challenges the CDMO classification for his company. He shares CTMC's mission to aid early clinical-stage firms like KSQ Therapeutics enter their clinical stage successfully. The podcast explores the collaboration between CTMC and KSQ, discussing the challenges and innovations in cell therapy development, experienced groups in the Tills industry uniting, cultural alignment and technical collaborations in biotech partnerships, the power of aligned incentives in collaborations, and excitement in advancing clinical data sets and cell therapies.

We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab. He also explains why an election year, all-time lows in public perception of the pharmaceutical industry, and inflation might create the perfect storm for real change. More than a gripe session, Allan offers up advice for biotech leaders entering the fray, shares his own ideas for systemic reform that would reward patients, not PBMs, and waxes on what, and who, it might take to change the broken paradigm.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/